Chemistry:Ranimustine
From HandWiki
Short description: Chemical compound
![]() | |
Clinical data | |
---|---|
Trade names | Cymerin |
Other names | 1-(2-chloroethyl)-1-nitroso-3-([(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl)urea |
AHFS/Drugs.com | International Drug Names |
Routes of administration | IV |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C10H18ClN3O7 |
Molar mass | 327.72 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Ranimustine (INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia[1] and polycythemia vera.[2]
It has never been filed for FDA evaluation in the United States , where it is not marketed.
References
- ↑ "[Chemotherapy of chronic myelogenous leukemia—VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis]" (in ja). Gan To Kagaku Ryoho 16 (11): 3573–9. November 1989. PMID 2817908.
- ↑ "[Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera]" (in ja). Gan To Kagaku Ryoho 15 (12): 3267–70. December 1988. PMID 3196045.
- (in Japanese) Cymerin サイメリン (PDF) Mitsubishi Tanabe Pharma. October 2007.
![]() | Original source: https://en.wikipedia.org/wiki/Ranimustine.
Read more |